Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
about
Noninvasive, Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson's Disease.Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's diseasePramipexole-induced somnolence and episodes of daytime sleep.Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data.Ropinirole and pramipexole, the new agonists.Treatment of early Parkinson's disease.The initial treatment of Parkinson's disease should begin with levodopa.Treatment of Parkinson's disease should begin with a dopamine agonist.Pharmacological treatment of Parkinson's disease.Effect of single amino acid substitution on oxidative modifications of the Parkinson's disease-related protein, DJ-1SLC11A1 (formerly NRAMP1) and disease resistance.The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's diseaseMeasuring therapy adherence in Parkinson's disease: a comparison of methodsRopinirole in the treatment of Parkinson's disease.Interaction of D₃ preferring agonist (-)-N⁶-(2-(4-(biphenyl-4-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264) with cloned human D₂L, D₂S, and D₃ receptors: potent stimulation of mitogen-activated protein kinParadoxical aspects of parkinsonian tremor.Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humansComparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson's Disease: A Network Meta-Analysis.Rotigotine transdermal patch for the treatment of Parkinson's Disease.Treatment in early Parkinson's disease: the Norwegian ParkWest study.Dopamine receptor agonists for Parkinson's disease.Early versus delayed initiation of pharmacotherapy in Parkinson's disease.Non-human primate models of PD to test novel therapies.Endogenous dopaminergic tone and dopamine agonist action.Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson's disease: the ADHESON study.Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease.Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).Dosing with ropinirole in a clinical setting.Determination of minimal clinically important change in early and advanced Parkinson's disease.Rasagiline treatment effects on parkinsonian tremor.Expression of Iron Transporters and Pathological Hallmarks of Parkinson's and Alzheimer's Diseases in the Brain of Young, Adult, and Aged Rats.Motor profile and drug treatment of nursing home residents with Parkinson's disease.C282Y and H63D Polymorphisms in Hemochromatosis Gene and Risk of Parkinson's Disease: A Meta-Analysis.
P2860
Q27301281-4E3093CD-3A4F-4CAC-89E1-79244A833B66Q28266116-AEB7B8A5-E23A-4A63-A7E4-7E8D8B52EC1FQ31422765-67E9AF71-C5C2-45B9-BF16-825C7ED9FEE2Q33529426-4D3D5A7C-3039-4325-8676-96C4E16412FFQ33714127-6B3FA7BD-509D-4050-A41A-C93A6A112493Q33714133-E587EEA1-0454-4B36-9885-525A085C6633Q33737387-5459BF45-98D3-4D53-8520-B98EC09B1CA1Q33737392-0E48559B-AC41-45BB-8C85-A181DA30FD20Q34048261-C4F8E0DC-3C3D-41CB-9FBE-C903DEDDCBFCQ34079628-2E1B2C3E-1E39-41C0-B575-E4BBEDEC6FF6Q34459115-92883E2B-A0BE-4016-8BB3-8EBD659FE5F5Q35042094-19516786-C0D4-468F-9095-1E5F9BE6B2D7Q36053229-78A458B8-0A62-40CE-B307-8CC760C3AC23Q36142605-5C149F17-DEDB-44EE-95E9-BE04CAC26761Q36181342-DBDF3314-DAB4-4F51-B249-5B013FFE2AEFQ36575989-E20348DF-E55C-4248-90A3-F614C1C3347AQ36987111-B982FF64-6FF6-4B4D-BF69-880EC5A5AE6BQ37161380-AF0EE3E7-2039-446C-8F9D-55F0E005771FQ37736512-11695FF8-8EEE-45E2-9000-0B926522637EQ37982789-BEE02D0D-1B26-40E2-9DE8-B3D29AD1D30EQ38063341-F0F10397-C1E2-43AC-81D4-2F3B00B25C55Q38169202-586ECBC2-3D5E-44CF-B27A-9282F0137898Q38206403-61ACF2B3-9DCE-48FF-8C60-BF3DFC5046CAQ39229450-2B74D739-EF46-4F6D-864B-A0E48F98CD2DQ39426348-8524E4B8-0C62-4B9A-BFA8-555EB6C7F43FQ43429609-556CD57D-1BB7-48EE-B3F4-894B6E841863Q43461514-2015C470-7F09-4EB0-9A55-40D0C9E606DCQ43693344-4C7A2CA8-F163-4F6B-9DAA-CC8EE4A84F83Q44133261-F962F815-CF04-4B8D-9BF5-0F34621F0DBCQ44778532-54C290A5-3E71-4B14-AC1C-7F9412A0A59BQ46621813-C87A620F-6D2F-4546-93A6-AB3F34287BD4Q48541060-02F66A46-9471-441F-824D-ED601E6EB6D0Q50732522-481B31B1-F7A2-4D79-BD04-F2E8E55DC83FQ53181763-51344B26-9BAF-4251-B721-281ED99DE41F
P2860
Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
description
im Januar 1998 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 January 1998
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 1998
@uk
name
Ropinirole in the treatment of ...... year levodopa-controlled study
@en
Ropinirole in the treatment of ...... year levodopa-controlled study
@nl
type
label
Ropinirole in the treatment of ...... year levodopa-controlled study
@en
Ropinirole in the treatment of ...... year levodopa-controlled study
@nl
prefLabel
Ropinirole in the treatment of ...... year levodopa-controlled study
@en
Ropinirole in the treatment of ...... year levodopa-controlled study
@nl
P2093
P2860
P50
P356
P1433
P1476
Ropinirole in the treatment of ...... trolled study. 056 Study Group
@en
P2093
P2860
P356
10.1002/MDS.870130111
P407
P577
1998-01-01T00:00:00Z